Acurx Pharmaceuticals reported significant progress in Q3 2025, marked by a successful reverse stock split, patent grants, and promising updates on its innovative drug pipeline for antibiotic-resistant infections.

• Achieved compliance with NASDAQ listing requirements post 1-for-20 reverse stock split and met minimum equity thresholds.
• Secured a new patent in Australia for DNA polymerase 3C inhibitors, further strengthening intellectual property portfolio.
• Participated in ID Week to present compelling data on ibezapolstat’s microbiome-sparing properties, reinforcing its efficacy against C. diff infections.
• Published collaborative research in Nature Communications showcasing ibezapolstat’s unique binding conformation to its target, enhancing the scientific foundation for continued development.
• Actively pursuing funding opportunities for a phase three clinical trial program for ibezapolstat, which has FDA QIDP and FAST TRACK designations.